Intarcia raises $210M to advance once-yearly diabetes drug

11/16/2012 | American City Business Journals · Mass High Tech (Boston)

Intarcia Therapeutics raised $210 million in a preferred stock sale and private debt placement. The company will use the proceeds to initiate late-stage trials of ITCA-650, an experimental type 2 diabetes drug intended to be administered once a year. Intarcia plans to submit the drug for approval in 2015.

View Full Article in:

American City Business Journals · Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA